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Objectives: Various focal brain lesions are primarily caused by excessive glutamate release. An easy and
convenient in vivo striatal lesion model was developed in which reliable and controllable lesion sizes
were created by glutamate for evaluation of neuroprotective agents.
Materials and Methods: Dose-dependent striatal lesions were created by intrastriatal infusion of sodium
glutamate in anesthetized male Sprague-Dawley rats (250e350 g). The lesion sizes were estimated with
a 2% triphenyltetrazolium chloride stain. Motor disturbances were evaluated by the rotarod test and
rotational behavior test. This experimental model was attested with neuroprotective effects of gran-
ulocyte colony-stimulating factor (G-CSF, 200 mg/kg), a cytokine growth factor, and estradiol (2 mg/kg), a
female sex hormone.
Results: Intrastriatal infusion of 2e6 mmol of 1 M (i.e., 2 Osm) sodium glutamate produced dose-
dependent (or controllable) increases in sizes and volumes of striatal lesion in which unpredictable
data were also included in analyses. The infusion rate appeared not to affect the lesion size or volume.
Although the 2 Osm (1 M) glutamate solution had a much higher osmolarity than brain extracellular ﬂuid
(0.3 Osm), control infusions with the 2 Osm of glucose or sodium chloride (NaCl) produced only
negligible lesions. The striatal lesion or volume induced by glutamate (4 mmol, 1 M) was reduced by
pretreatment with the neuroprotective agents G-CSF and estradiol. The motor disturbance caused by
glutamate infusion was also improved by G-CSF administration.
Conclusion: Local intrastriatal infusions with controlled doses of glutamate can create a reliable,
controllable striatal lesion size. This model is easy and convenient for evaluation of neuroprotective
agents.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Glutamate is a major neurotransmitter at most excitatory syn-
apses in the mammalian central nervous system. It activates two
kinds of receptors, the ionotropic and metabotropic glutamate re-
ceptors [1,2]. The ionotropic action of glutamate acts on three
distinct receptor systems, the N-methyl-D-aspartate (NMDA), a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and kainateand Toxicology, Tzu Chi Uni-
ien, Taiwan. Tel.: þ886 3
ddhist Compassion Relief Tzu Chireceptors [3], to mediate most of the excitatory synaptic trans-
missions in the brain. Excitotoxicity of over-released glutamate is a
key factor in central neuronal loss consequent to hypoxiceischemic
insult [4].
The extracellular concentration of glutamate is normally main-
tained at w1 mM by sodium (Naþ) ﬂux-coupled transport [5].
Excessive releases and/or accumulations of glutamate in the
extracellular ﬂuid commonly occur in brain injuries, including
acute insults (such as cerebral ischemia, cerebral hemorrhage, brain
infection, traumatic brain injury) and chronic neurodegenerative
diseases (such as Huntington’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis) [6,7]. Brain injuries cause falls in Naþ
gradients and cellular energy reserves, leading to an increased
release and impaired uptake of glutamate in which toxic extra-
cellular glutamate is built up. This toxic glutamate induces anFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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neuronal cell damage and death. Because the mechanisms of the
neuronal damage or death caused by glutamate are not yet well
clariﬁed, therapeutic and preventive approaches for brain injuries
remain unsatisfactory.
The striatum, a main input nucleus of the basal ganglia, receives
a great number of glutamatergic afferents from the cortex and
thalamus [8]. Therefore, glutamate excitotoxicity in striatum dis-
orders has attracted considerable attention [6,9]. Focal striatal le-
sions (injuries) have been produced by local administration of
quinolinate (an NMDA agonist of glutamate) or/and kainate (a non-
NMDA agonist of glutamate) into the striatum for evaluation of
various neuroprotective agents [10e12]. Administration of quino-
linate or kainate into the striatum causes excitotoxicities by over-
stimulation of the glutamatergic receptors. It is still important to
ask whether a neuroprotective agent effective in striatal damage
induced by kainate or quinolinate is also effective in that induced
by directly increasing the extracellular glutamate concentration by
direct injection of glutamate in the striatum. As far as we know, the
evaluation of neuroprotective agents in striatal lesions induced by
directly increasing the extracellular glutamate concentration in the
striatum has seldom been addressed.
The mechanisms of neuronal damage or death caused by
glutamate are not yet well clariﬁed. Therefore, developing a good
animal model, in which the degree of neuronal damage or death
and the size of the damaged brain area (lesion) produced by
glutamate are reliable and controllable, has become very impor-
tant. In this experiment, lesions were produced in the striatum,
because the approach to the nucleus is easy with insertion of a tube
for glutamate microinfusion. In addition, evaluation of motor
disturbance is possible because striatal lesions disturb motor
function. This is important because evaluation of therapeutic ef-
fects should be based on functional recovery as well as biochemical,
morphological, and histological recovery.
This study reports a novel focal striatal lesion model in which
lesion sizes were reliable and controllable, and lesion-induced
motor disturbance could be evaluated. This model has proven to
be valid and convenient for evaluation of neuroprotective agents.
2. Materials and methods
2.1. Chemicals
Chloral hydrate, urethane, sodium glutamate, triphenylte-
trazolium chloride (TTC), and estradiol were purchased from
Sigma-Aldrich (St Louis, MO, USA). Granulocyte colony-stimulating
factor (G-CSF, 300 mg in 0.7 mL) was purchased from Kirin Brewery
Company (Gunma, Japan). Chloral hydrate (0.04 g/mL) or urethane
(0.5 g/mL) was dissolved in normal saline and stored at room
temperature for further use. Sodium glutamate (1 M) and TTC
(0.02 g/mL) were dissolved in normal saline and stored at 4C. G-
CSF (300 mg in 0.7 mL) was stored at 4C. G-CSF (200 mg/kg) and
estradiol (2 mg/kg) were freshly dissolved in 0.5 mL normal saline
and 1.0 mL 1% dimethyl sulfoxide, respectively.
2.2. Surgical procedures
The experiments were carried out in accordance with the Na-
tional Institute of Health Guide for the Care and Use of Laboratory
Animals and with the Guidelines of the Tzu Chi University Ethical
Committee for Animal Research. The Committee has approved this
investigation.
Male Sprague-Dawley rats (250e350 g) were anesthetized with
urethane 1.0 g/kg or chloral hydrate 0.04 g/kg. All surgical pro-
cedures were done under aseptic conditions. The femoral vein wascannulated with a PE-50 polyethylene tube for ﬂuid supplements
and drug administration, and the femoral artery for monitoring of
arterial blood pressure. The arterial blood pressure and heart rate
were recorded and computed with a MP35 ampliﬁer (BIOPAC Inc,
Goleta, CA, USA) and stored in a computer. The body temperature
(rectal temperature) was automatically maintained at 37.5  0.5C
by a rectal temperature sensor and a heating pad (CMA-150; CMA
Microdialysis AB, Stockholm, Sweden). The head of the rat was
ﬁxed on a Stoelting stereotaxic instrument (Stoelting Co, Wood
Dale, IL, USA). A midline incision on the scalp exposed the skull for
insertion of a microinfusion tube (28-gauge, Small Parts, Inc.,
Miami, FL, USA). To facilitate insertion of the infusion tube into the
striatum, a hole about 1.0e1.2 mm was created in the skull with a
dental drill at 0.5 mm rostral to the bregma, 3.0 mm lateral to the
midline, and 6.0 mm ventral to the surface of the cortex. Animals
were stabilized for 20 minutes before experiments.
2.3. Creation of striatal lesions
To create striatal lesions, sodium glutamate was microinjected
through the infusion tube implanted in the striatum as described
above. The lesion was routinely created unilaterally on the right
striatum. One end of the infusion tube was connected to PE-50
polyethylene tubing and the other end to the needle of a Hamil-
ton syringe (Hamilton Company, Reno, NV, USA). The microinfusion
was accomplished by pushing the Hamilton syringe with a CMA-
200 microinfusion pump (CMA Microdialysis).
Estradiol or G-CSF was used for pretreatment 30 minutes before
the glutamate infusion. For the rotational behavior test, G-CSF
(200 mg/kg, subcutaneously) was given immediately after and every
24 hours for 1 week after glutamate administration.
2.4. Measurement of striatal lesions
To evaluate lesion volume, animals were sacriﬁced 18 hours
after the infusion of glutamate and the brains were removed. The
brains were ﬁxed with rat brain stainless steel coronal slices
matrices RBS-SS1-C (ASI Instruments, Inc, Warren, MI, USA) in 9%
normal saline at 4C. Coronal sections (1 mm thickness) were made
from the olfactory bulb to the cerebellum. The sections were taken
at 2 mm, 1 mm, 0 mm, 1 mm, 2 mm, and 3 mm from the
injected site (0 mm) to contain the entire lesion. They were placed
in 2% TTC in normal saline and stained for 20 minutes at 37C in the
dark, then washed twice with saline, and ﬁxed with 4% para-
formaldehyde for 30 minutes at room temperature.
TTC is a reagent for oxidative enzymes ﬁrst introduced by Jes-
taedt and Sandritter [13] as a stain to detect ischemic injury of the
myocardium. TTC is widely applied in localization of various brain
injuries. This salt is reduced by accepting a proton from succinate
dehydrogenase in the inner membrane of the mitochondria to form
red insoluble formazan. Therefore, in an area with inactive en-
zymes, the lesion area is not stained and appears pale. The pale area
(not stained by TTC) was deﬁned as the core area, a slightly
reddened area (partially stained by TTC) was deﬁned as the pen-
umbra area, and a dark red area (completely stained by TTC) was
deﬁned as the undamaged area.
Anterior face images of collected TTC sections were photo-
graphed and the images stored as JPG computer ﬁles. Image J
software (NIH, Bethesda, MD, USA) was used to measure and
analyze the lesion size (area) and volume [14].
2.5. Motor behavior test (rotational behavior test)
Rotational behavior was measured 7 days after the administra-
tion of glutamate (4 mmol, 1 M, 0.05 mL/min, intrastriatally).
Fig. 1. Effects of continuous 80-minute infusion of sodium glutamate into the right
striatum on ipsilateral striatal blood ﬂow as measured with a laser Doppler ﬂowmeter
probe. * p < 0.05 versus normal saline group (unpaired t test).
Fig. 2. Effects of striatal lesion sizes and volumes upon infusion of normal saline
(sodium glutamate 0 mmol), and glutamate 2 mmol, 3 mmol, 4 mmol, and 6 mmol in rats
anesthetized with (A) urethane (1.5 g/kg) and (B) chloral hydrate (0.4 g/kg). Normal
saline and sodium glutamate (1 M or 2 Osm) were infused at 0.05 mL/min for 120 min,
40 min, 60 min, 80 min, or 120 min. The rats were sacriﬁced 18 h after infusion.
Representative brain slides (A) were stained with triphenyltetrazolium chloride (TTC).
Scale bar, 1 mm. The histogram summarizes the results. For A, *, p < 0.01 versus 0 mmol
group (vehicle with normal saline for 120 min); **, p < 0.01 versus 2 mmol group;
***, p < 0.01 versus 3 mmol group; ****, p < 0.01 versus 4 mmol group. For B, *, p < 0.001
versus 0 mmol group; **, p < 0.001 versus 2 mmol group; ***, p < 0.001 versus 3 mmol
group; ****, p < 0.01 versus 4 mmol group (unpaired t test).
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observe rotational behavior. Complete rotation (360) was recorded
every 5 minutes in both clockwise (ipsiversive to the infused
hemisphere) and counterclockwise (contraversive to the infused
hemisphere) directions for 60 minutes according to the method of
Altar et al [15] withmodiﬁcations. Numbers of complete ipsiversive
and contraversive rotations were recorded every 5 minutes for
60 minutes. I/(I þ C) indicates ipsiversive rotations/(ipsiversive ro-
tations and controversive rotations), reﬂecting changes in rotational
behavior. Rats were sacriﬁced immediately after the measurement.
2.6. Rotarod test
Motor impairment was assessed by a TSE RotaRod System
equipment (Technical & Scientiﬁc Equipment GmbH, Bad Homburg,
Germany). Brieﬂy, the animal was place on a rod, a 5 cm diameter
steel beam covered with high-proﬁle rubber to ensure ﬁrm grip-
ping. This rod turned on its longitudinal axis at an initial rate of
4 rpm and accelerated to 40 rpm in 300 seconds. Side panels were
inserted at each end of the rod to prevent escape from the appa-
ratus. The training room for the rotarod test was maintained at a
temperature 22e24C, and noise was kept to a minimum.
Before the rotarod test, the rats had daily training sessions, in
which they were gently moved to the training room and gently
placed on the rodwith the orientation opposite to that of the already
rotating rod so that theycould acquire thenecessary skilledbehavior
to prevent a fall. Rats were allowed into the experiment when they
could stay on the rod for at least 150 seconds. The rotarod test was
done10 times1hourbefore theglutamate infusionandat17hours, 3
days, 5 days, and 7 days after the glutamate infusion. The test scored
based on the rats’ baseline ability. Rats that did not fall off the rod
within 10minuteswere given amaximumscore of 600 seconds [16].
2.7. Statistical analysis
All data are presented as mean  standard error of the mean.
Differences between groups with identical treatments were
determined with unpaired Student t test. In all cases, differences
were considered signiﬁcant at p  0.05.
3. Results
3.1. Cardiovascular parameters
In urethane-anesthetized rats, the basal systemic arterial pres-
sure and heart rate were 101.6  3.0 mmHg and 429.0  19.1 beats/
min, respectively. Theywere not altered bymicroinfusion of sodium
glutamate and normal saline (vehicle) into the striatum. The gluta-
mate infusion into the striatum, however, induced a striatal blood
ﬂow increase (124.6  2.6% of basal level) in 5 minutes and a
maximum increase (153.319.36% of basal level) in 60minutes. The
ﬂowgradually returned to thebasal level in120e150minutes (Fig.1).
The striatal blood ﬂowwas not affected by microinfusion of vehicle.
In chloral hydrate-anesthetized rats, the basal systemic
arterial pressure and heart rate were 99  5.0 mmHg and
400.0  21.3 beats/min, respectively, essentially similar to those in
urethane-anesthetized rats. These parameters, however, started to
ﬂuctuate and increase at 60 minutes after anesthesia, because
chloral hydrate is a short acting anesthetic agent. A supplemental
dose of 0.1 g/kg was subcutaneously administered to maintain
stable blood pressure. The glutamate infusion into the striatum
essentially induced an increase in striatal blood ﬂow similar to that
in the urethane-anesthetized rats.
Because rats anesthetized with urethane were unable to wake
up in 24 hours, they were used for long-term monitoring ofcardiovascular parameters (Fig. 1). However, they tended to suffo-
cate under 24-hour anesthesia conditions. By contrast, those
anesthetizedwith chloral hydratewoke up in 3e4 hours, and hence
suffocation was generally avoided. In the following experiments
(Figs. 2e7), therefore, all rats were anesthetized with chloral
hydrate.3.2. Dose-dependent effects on striatal lesions
Fig. 2 shows that unilateral intrastriatal glutamate infusions
induced similar dose-dependent increases in striatal lesion sizes
Fig. 3. Triphenyltetrazolium chloride (TTC)-stained brain slices indicate striatal lesion
sizes produced by intrastriatal infusion of (A) the same doses and (B) different doses of
glutamate (1 M, 0.05 mL/min) on both sides of a rat brain. The doses were adjusted by
injection time as in Fig. 2. The rats were sacriﬁced 18 h after infusion for TTC staining of
brain slides. Note the similarity or reliability (A) and the dose-dependency (B) of the
lesion sizes on both sides of the brain. Scale bar, 1 mm.
Fig. 5. The effects of estradiol or granulocyte colony-stimulating factor (G-CSF) on
striatal lesion sizes (A) and volumes (B) produced by intrastriatal infusion of glutamate
(4 mmol, 1 M, 0.05 mL/min) in rats anesthetized with chloral hydrate (0.4 g/kg).
Estradiol or G-CSF was administered intravenously 30 min before the glutamate
infusion and the rats were sacriﬁced 18 h later. Brain slices were stained with TTC (A).
Arrows indicate the lesion sizes. The histogram summarizes the experimental results
(B). *, p < 0.05, **, p < 0.01 versus the control group (glutamate and vehicle), unpaired t
test. Scale bar, 1 mm.
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the lesion sizes and volumes are controllable. The average lesion
volumes with 2 mmol, 3 mmol, 4 mmol, and 6 mmol of sodium
glutamate, were 0.5  0.1 mm3 (n ¼ 10), 3.2  0.5 mm3 (n ¼ 8),
10.5  1.9 mm3 (n ¼ 14), and 16.7  1.7 mm3 (n ¼ 13), respectively,
in rats anesthetized with urethane (1.5 g/kg; Fig. 2A). The lesion
volumes with 2 mmol, 3 mmol, 4 mmol, and 6 mmol of sodium
glutamate, were 2.0  0.4 mm3 (n ¼ 10), 5.2  0.5 mm3 (n ¼ 8),
10.7  0.9 mm3 (n ¼ 14), and 18.1 1.9 mm3 (n ¼ 13), respectively,
in rats anesthetized with chloral hydrate (0.4 g/kg; Fig. 2B). Highly
reliable (less varied) lesion sizes could be created on both sides of
the striatum of the same rat with the same dose of glutamate
(Fig. 3A). Furthermore, markedly dose-dependent lesion sizes were
produced by different doses of glutamate on both sides of a rat
brain (Fig. 3B). Because 4 mmol produced a moderate lesion volume
(Figs. 2, 3), this dose was used for the experiments in Figs. 5e7.Fig. 4. Triphenyltetrazolium chloride (TTC)-stained brain slices show that infusion
(0.05 mL/min) of various doses of high osmolar (A) sodium chloride (NaCl) and (B)
glucose solutions into the striatum of chloral hydrate (0.4 g/kg). Anesthetized rats
produced only tiny lesions (arrows) that can be ignored. The doses were adjusted by
injection time as in Fig. 2. The rats were sacriﬁced 18 h after the infusion for TTC
staining of brain slides. 0 mmol indicates vehicle (normal saline) infusion for 2 h. Scale
bar, 1 mm.The infusion rate did not appear to affect the lesion size or
volume, since lesion sizes caused by the same dose (4 mmol in 4 mL)
of 1 M glutamate infused at different rates (0.3 mL/min and 0.05 mL/
min, n ¼ 3) showed no signiﬁcant differences (data not shown).3.3. Negligible effect of high osmolar solutions on lesion size
The glutamate (1 M) used in this experiment was 2 Osm. This
osmolarity was much higher than that of plasma or extracellular
ﬂuid (0.29 Osm). It was tested whether this high concentration of
glutamate causes osmotic damage to the brain. Fig. 4 shows that
microinfusion of a 2 Osm solution of 1 M sodium chloride (NaCl) orFig. 6. Effects of granulocyte colony-stimulating factor (G-CSF) on rotational behavior
produced by unilateral intrastriatal infusion of glutamate (4 mmol, 1 M, 0.05 mL/min).
G-CSF was administered subcutaneously immediately before glutamate infusion and
every day until the day the animals were sacriﬁced. The glutamate infusion induced
motor disturbance as judged by a rotational behavior test 1 week after the lesion was
induced. Numbers of complete ipsiversive and contraversive rotations were recorded
every 5 min for 60 min. I/(I þ C) indicates ipsiversive rotations/(ipsiversive rotations
and controversive rotations), reﬂecting changes in rotational behavior. *, p < 0.05
versus the control group (glutamate and vehicle), unpaired t test.
Fig. 7. Effects of granulocyte colony-stimulating factor (G-CSF) on rotarod performance
in rats subjected to intrastriatal infusion of glutamate (4 mmol, 1 M, 0.05 mL/min). G-CSF
was administered subcutaneously right before glutamate infusion and every day until
the day the animals were sacriﬁced. Rotarod performance was tested 1 h before (1 h)
glutamate infusion and 17 h, 3 days, 5 days, and 7 days after glutamate infusion.
*, p < 0.01 versus the glutamate group (paired t test); **, p < 0.05 versus 1 h (paired
t test); ***, p < 0.05 versus 1 h (paired t test); ****, p < 0.01 versus1 h (paired t test);
##, p < 0.01 versus 1 h (paired t test).
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These results suggest that the 1 M (2 Osm) glutamate used in this
experiment does not produce signiﬁcant osmotic damage.
3.4. Validity of the model for studying neuroprotecting agents
In order to test whether this animal model was valid for
studying neuroprotective agents, the effects of G-CSF and estradiol
on unilateral glutamate-induced lesion sizes and volumes were
examined (Fig. 5). Pretreatment with either drug signiﬁcantly
reduced the glutamate-induced striatal lesion size and volume.
These ﬁndings indicate that this model is valid for testing neuro-
protective agents.
3.5. Motor function assessed by rotational behavior test and
rotarod test
A unilateral intrastriatal injection of glutamate (4 mmol, 1 M,
0.05 mL/min) inducedmotor disturbance as judged by the rotational
behavior test 1 week after induction of the lesion (Fig. 6). Motor
disturbance was characterized by increased (biased) ipsiversive
rotation activity as indicated by an increase in the ratio of I/(Iþ C) in
the glutamate and vehicle group, with a decrease in the glutamate
and G-CSF group.
Fig. 7 shows that a unilateral striatal lesion caused motor
disturbance as judged by the rotarod test. Motor disturbance
improved with subcutaneous G-CSF administration immediately
before glutamate infusion and every day until the day the animals
were sacriﬁced.
These ﬁndings indicate that the current model is valid for




This investigation demonstrated for the ﬁrst time a novel rat
model in which dose-dependent increases in striatal lesion sizes or
volumeswere produced by intrastriatal infusion of controlled doses
of sodium glutamate (2e6 mmol, 1 M; Figs. 2 and 3). Although a
glutamate solution of 1 M or 2 Osm has a much higher osmolarity
than brain extracellular ﬂuid (0.3 Osm), the osmolarity itself did not
create a signiﬁcant lesion (Fig. 4). This model is valid in studying theeffects of neuroprotective agents, as shown by ﬁndings that
glutamate-induced striatal lesions were reduced by two neuro-
protective agents, estradiol and G-CSF (Fig. 5). Furthermore, the
lesion-induced increase in ipsiversive rotational activity was
attenuated by G-CSF (Fig. 6) and the lesion-induced decrease in
motor performance on the rotarod test was improved by G-CSF
(Fig. 7). Therefore, this study established a novel focal striatal lesion
model in which local intrastriatal infusion of controlled doses of
glutamate produced controllable and reliable lesion sizes and vol-
umes. This model is easy and convenient for application in studying
neuroprotective agents.
4.2. Glutamate-induced lesion size is controllable and reliable
In this experiment, glutamate doses in the range of 2e6 mmol
(1 M) were able to produce dose-dependent and controllable lesion
sizes (Fig. 2). The lesion size caused by the same (equal) dose of
glutamate, however, varied in a somewhat wider range. This could
be attributed to individual animal variation and not to technical
problems, because highly reliable (less varied) lesion sizes were
created by intrastriatal infusion of the same dose of glutamate into
both sides of the same rat brain (Fig. 3A), and markedly dose-
dependent lesion sizes were produced by intrastriatal infusion of
different doses of glutamate into both sides of the same rat brain
(Fig. 3B). Increasing the number of experimental animals to 14 or 15
could easily solve the problem of the wide variation in lesion sizes
(Fig. 2). These ﬁndings indicate the reliability of the present
technique.
Other models such as the middle cerebral artery occlusion
(MCAO), middle cerebral artery ligation, endothelin-1 [14,17],
collagenase infusion [18], and blood infusion models [18] have dis-
played unstable results, such as unexpected lesion sizes or damages,
although all operative procedures and conditions were strictly
standardized. To solve this problem, data selectionwas used in these
models to minimize the standard error of the mean. Because the
MCAOmodel usually has an infarct volume up to 400mm3, animals
with no or minimal infarcts (<60 mm3) in one study were excluded
from the analysis before unblinding, but included in the treatment
group [14]. In this experiment, the lesion size varied somewhat, but
there were never unexpectedly large or small lesions. Nevertheless,
exclusion of data from analyses was avoided by simply increasing
the number of animals to 14 or 15 (Fig. 2).
4.3. High-concentration glutamate and its osmotic effects
Microdialysis studies have conﬁrmed the release of various
excitatory amino acids in the extracellular space in rat brains sub-
jected to MCAO [19]. MCAO induced a rapid and marked increase in
the extracellular concentrations of glutamate up to 14 fold of the
physiological level, <1e10 mM [20]. In this study, microinjection of
sodium glutamate at a concentration lower than 0.34M, or
0.68 Osm (1.0 mmol or 2.0 mmol, infused at 0.3 mL/min for 3.3 min)
failed to produce a lesion (data not shown). The failure was prob-
ably due to faster clearance of the glutamate, very slow infusion of
the glutamate, or glutamate-induced increase in blood ﬂow (Fig. 1).
Therefore, a high concentration 1 M sodium glutamate, about 1e
10  106 times higher than the physiological level, was used to
produce striatal lesions.
Using high concentration glutamate (1 M) to produce lesions in
this experiment inevitably involved an osmotic effect on the lesion
size. The osmolarity of the glutamate was IM or 2 Osm (2 mmol,
3 mmol, 4 mmol, and 6 mmol in 2 mL, 3 mL, 4 mL, and 6 mL, respectively).
Thiswas higher than the plasmaosmolarity of 0.29Osm. An infusion
of 2 OsmNaCl (1M) or glucose (2M) into the striatum, however, did
not produce signiﬁcant lesions (Fig. 4). This indicates that a 1 M
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lesions, and the lesions produced by various doses of glutamate can
be almost attributed to the excitotoxic effect of glutamate.
4.4. The model is valid for investigation of neuroprotective agents
G-CSF, a member of the cytokine family of growth factors, pro-
tects against glutamate-induced excitotoxicity in cell culture and
reduces infarction volume after focal cerebral ischemia [21].
Estradiol, a female hormone, possesses a wide spectrum of pro-
tective mechanisms against multiple toxic insults, as shown in not
only an in vitro cell culturemodel [22] but also in an in vivomodel of
global and transient ischemia [23]. In this study, pretreatment with
G-CSF or estadiol reduced the size and volumes of glutamate-
induced striatal lesions (Fig. 5). Furthermore, pretreatment with
oroxylin-A, an antioxidant biphenolic compound, also reduced
lesion size (data not shown). These pretreatment experiments
show the validity of the present model for assessing the effect of
neuroprotective drugs.
4.5. The model is valid for evaluation of motor function impairment
An ideal in vivo brain damage model has to be valid for evalu-
ating motor function impairment in addition to lesion sizes so the
effects of neuroprotective agents can be properly assessed. In this
experiment, the lesion involved primarily the rostral striatum,
which relaysmotor control signals of the basal ganglia. An increased
(biased) rotational activity to the lesion side (ipsiversive rotational
behavior) was detected 7 days after the lesion (Fig. 6). Impairment
of rotarod performancewas detected at 17 hours, 3 days, 5 days, and
7 days after induction of lesions in the rats. G-CSF attenuated the
increased ipsiversive rotational activity and improved the rotarod
performance compared with vehicle-treated animals. Hence, our
model is valid for evaluating motor function impairment.
5. Conclusion
This study established a novel focal striatal lesion model in
which local intrastriatal infusion of controlled doses of glutamate
produced stable, controllable, and reliable focal striatal lesions. This
model is easy and convenient for application in studying the neu-
roprotective mechanisms of neuroprotective agents and the path-
ophysiological mechanisms in glutamate-induced brain damage.
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